Antimicrobial

UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority ReviewUTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review

UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review

UTILITY has received a Prescription Drug User Fee Act (PDUFA) target action date of April 24, 2024FDA granted Qualified Infectious…

1 year ago
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor NetworkNovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network

EMERYVILLE, CA and BOULDER, CO / ACCESSWIRE / January 9, 2024 / NovaBay Pharmaceuticals, Inc. (NYSE American:NBY) and Sonoma Pharmaceuticals,…

1 year ago
CorMedix Inc. Announces Commercial and Operational UpdatesCorMedix Inc. Announces Commercial and Operational Updates

CorMedix Inc. Announces Commercial and Operational Updates

BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

1 year ago
Basilea provides portfolio status updateBasilea provides portfolio status update

Basilea provides portfolio status update

Clinical portfolio substantially strengthened through business development in 2023; two phase 3 studies expected to start in 2024Cresemba in-market sales…

1 year ago
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 RevenuesPacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to…

1 year ago
ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergyALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy

ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy

– PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii –…

1 year ago
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsSpero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

$95 million in development milestones payable over two years, as part of GSK license agreementCAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE…

1 year ago
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024

Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024

LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on…

1 year ago
CorMedix Inc. Announces Appointment of Chief Legal OfficerCorMedix Inc. Announces Appointment of Chief Legal Officer

CorMedix Inc. Announces Appointment of Chief Legal Officer

BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

1 year ago
Preventogen is a New Tool in the Fight Against Antibiotic-Resistant Infections Caused by Superbugs, a Leading Cause of Death WorldwidePreventogen is a New Tool in the Fight Against Antibiotic-Resistant Infections Caused by Superbugs, a Leading Cause of Death Worldwide

Preventogen is a New Tool in the Fight Against Antibiotic-Resistant Infections Caused by Superbugs, a Leading Cause of Death Worldwide

Preventogen's FDA-Cleared Microbicidal Liquid Polymer Ensures the Eradication of These Dangerous Pathogens on Contact While Forming a More Effective and…

1 year ago